Back to top

Image: Bigstock

Thermo Fisher Scientific, Inc.

Read MoreHide Full Article

Thermo Fisher ended the fourth quarter 2017 on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate. We are encouraged by the company’s solid international performance with strong growth in the Asia-Pacific and the emerging markets. Also, a series of product launches along with major progress in precision medicine initiatives benefited the company’s performance. Thermo Fisher’s FEI acquisition has already started to boost analytical instruments portfolio. Also in 2017, the company deployed $7.8 billion on strategic acquisitions, adding leading biopharma contract development and manufacturing services through Patheon. In the past three months, Thermo Fisher is trading above the broader industry.On the flip side, in the reported quarter, the company’s business segments were impacted by strategic investments and unfavorable business mix. Also, competitive headwinds and rising operating costs continue to pose a threat.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Thermo Fisher Scientific Inc. (TMO) - free report >>

Published in